AstraZeneca Planning China Business Spin Off -FT
(Reuters) – Drugmaker AstraZeneca is drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is being viewed as an option, the Financial Times reported on Sunday. A separation might not ultimately take place, the report said, citing people familiar with the matter, with one of them saying…
